FDA Approves IV Form of Uptravi as Short-term Option to Oral Therapy

FDA Approves IV Form of Uptravi as Short-term Option to Oral Therapy

301454

FDA Approves IV Form of Uptravi as Short-term Option to Oral Therapy

The U.S. Food and Drug Administration (FDA) has approved an intravenous form of Uptravi (selexipag) — one infused directly into the bloodstream — for people with pulmonary arterial hypertension (PAH) temporarily unable to take oral medicines. The new intravenous, or IV, formulation is intended to prevent treatment interruptions in adults with World Health Organization functional class II or III PAH, meaning individuals with slight (class II) or marked (class III) limitations on physical activity. “Given the progressive nature…

You must be logged in to read/download the full post.